The Ministry of Health (Kemenkes) recorded 87 districts/cities with a weekly average vaccination rate above the Indonesian average, currently recorded at 2,024.52 doses as of Thursday, March 17, 2022.
The top three districts/cities with weekly averages exceeding 14,222 doses are Bogor, Bandung, and Sukabumi, with values of 25,291 doses, 15,027 doses, and 14,222 doses respectively.
Bogor ranks first with a weekly average vaccination of 25,291 doses. Vaccine usage up to yesterday was recorded at 5.64 million doses. In the national dashboard recapitulation, the first dose vaccination achievement in this region has reached 87.47 percent.
According to the Ministry of Health, the available vaccine stock in this district will run out in the next 12 days. This remaining usage period is calculated from the remaining stock of 305,100 doses, and vaccine usage is the highest nationally.
Bandung follows in second place. The first dose vaccination achievement in this district has reached 89.6 percent. Compared to the previous week, the weekly average vaccination in this district reached 15,027 doses. The currently available vaccine stock is 266,180 doses. This stock is estimated to run out in the next 17 days.
Next is Sukabumi with a weekly average vaccination of 14,222 doses; first dose vaccination coverage has reached 88.03 percent. Jember, with 14,138 doses and a first dose vaccination achievement of 79.81%, and Cirebon, with a weekly average vaccination of 11,723 doses and a first dose vaccination achievement of 90.23%, also show high vaccination rates.
Some of the areas outside Java with the highest weekly average vaccination rates include Bolaang Mongondow, Boalemo, and Bolaang Mongondow Utara, with weekly averages of 1,281 doses, 362 doses, and 398 doses respectively.
The government urges everyone to help reduce COVID-19 transmission by always wearing masks, maintaining distance, and frequently washing hands with soap and running water. Avoiding crowds and reducing mobility also contribute to suppressing the spread of the coronavirus.